Article

Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: The ARIC MRI Study

Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
Alzheimer's & dementia: the journal of the Alzheimer's Association (Impact Factor: 14.48). 04/2009; 5(3):207-14. DOI: 10.1016/j.jalz.2009.01.027
Source: PubMed

ABSTRACT Strokes, vascular risk factors, and apolipoprotein E (APOE) genotype are associated with cognitive decline in the elderly, but definitive evidence that these affect cognition as early as middle age is limited.
We describe the relationships of APOE genotype, stroke, and vascular risk factors with cognitive change over a 14-year follow-up in the Atherosclerosis Risk in Communities (ARIC) Study cohort recruited while in middle age.
Participants included a subset of the ARIC Study who underwent assessments of cognitive function and vascular risk factors. Four cognitive assessments were performed between 1990-1992 and 2004-2006. Cognitive assessments included the Delayed Word Recall (DWR) Test, the Digit Symbol Substitution (DSS) Test, and the Word Fluency (WF) Test. Vascular risk factors were assessed during the baseline visit in 1990-1992. Incident stroke was recorded over the 14 years of follow-up.
There were 1130 participants (mean age, 59 +/- 4.3 [SD] years; 62% women; 52% African-American) with longitudinal data. In multivariate, random-effects linear models adjusted for age, education, gender, and race, the risk factors diabetes and APOE epsilon4 genotype were independently associated with a decline in performance on the DSS test (both P < .005), whereas hypertension and stroke were not. For DWR, stroke and APOE epsilon4 genotype were independent predictors of decline (both P < .001). For the WF test, metabolic syndrome, hypertension, and stroke were independently associated with decline (all P < .005). No evidence of differential effects of risk factors on cognitive decline by race, gender, or interactions between risk factors was found.
The vascular risk factors diabetes and hypertension, a history of stroke itself, and APOE epsilon4 genotype independently contribute to cognitive decline in late middle age and early elderly years.

0 Bookmarks
 · 
114 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: -Target temperature management is recommended as a neuro-protective strategy after out-of-hospital cardiac arrest. Potential effects of different target temperatures on cognitive impairment commonly described in survivors are not sufficiently investigated. The primary aim of this study was to evaluate whether a target temperature of 33ºC compared to 36ºC was favourable for cognitive function, and secondary to describe cognitive impairment in cardiac arrest survivors in general. -Study-sites included 652 cardiac arrest survivors originally randomized and stratified for site to temperature control at 33ºC or 36ºC within the Target Temperature Management trial. Survival until 180 days after the arrest was 52% (33ºC n=178/328 36ºC n=164/324). Survivors were invited to a face-to-face follow-up and 287 cardiac arrest survivors (33ºC n=148/36ºC n=139) were assessed with tests for memory (Rivermead Behavioural Memory Test), executive functions (Frontal Assessment Battery) and attention/mental speed (Symbol Digit Modalities Test). A control-group of 119 matched patients hospitalized for acute ST-elevation myocardial infarction (STEMI) without cardiac arrest performed the same assessments. Half of the cardiac arrest survivors had cognitive impairment, which was mostly mild. Cognitive outcome did not differ (p >0.30) between the two temperature groups (33ºC/36ºC). Compared to STEMI-controls attention/mental speed was more affected among cardiac arrest patients, but results for memory and executive functioning were similar. -Cognitive function was comparable in survivors of out-of-hospital cardiac arrest when targeting a temperature of 33ºC and 36ºC. Cognitive impairment detected in cardiac arrest survivors was also common in matched STEMI-controls not having had a cardiac arrest. Clinical Trial Registration Information-ClinicalTrials.gov. Identifier: NCT01946932.
    Circulation 02/2015; DOI:10.1161/CIRCULATIONAHA.114.014414 · 14.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The ability for patients to understand their risk for disease is important to early intervention and effective treatment. The link between individual cardiovascular risk factors and cognition has been well-established. This study investigated the relationship between cognition and a combination of these factors through a single composite risk score. This study quantitatively summarized the strength of the association between composite cardiovascular risk scores and cognitive test performance using meta-analytic methods. One hundred and nine effect sizes were obtained from 19 studies employing 54,564 participants. Composite risk scores showed a significant association (r = -0.16) with cognitive test performance. Cognitive domain and age did not significantly modify this relationship. Composite cardiovascular risk scores can be useful indicators of future cognition. The development of a dementia risk score using similar risk factors could aid in the assessment and lifestyle interventions of persons at risk for dementia.
    Annals of Behavioral Medicine 01/2015; DOI:10.1007/s12160-014-9681-0 · 4.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The scientific literature supports a link between midlife adiposity and cognitive function or decline but most studies to-date have investigated only overall adiposity, often omitting important confounders from the analyses. We investigated in a cross-time design the relationships between two different midlife adiposity markers and subsequent cognitive function, testing midlife dietary patterns as a potential confounder of the associations. The study was based on the «Supplémentation en Vitamines et Minéraux Antioxydants» randomized trial (SU.VI.MAX, 1994-2002) and the SU.VI.MAX 2 observational follow-up study (2007-2009). A general-population cohort in France. N=2,817 individuals (1,493 men and 1,324 women) included in both the SU.VI.MAX and SU.VI.MAX 2 studies. The cognitive performance of 2,817 middle-aged adults participating in the SU.VI.MAX (Supplémentation en Vitamines et Minéraux Antioxydant) study was assessed in 2007-2009 using 6 neuropsychological tests. Principal component analysis was used to derive specific cognitive scores. A composite cognitive score was also computed. Body mass index (BMI) and waist circumference (WC) were measured 13 years earlier (1994). Associations between midlife adiposity and cognitive functioning were estimated through covariance analyses. After adjustment for obesity-related cardio-metabolic parameters, higher BMI and larger WC at midlife predicted lower executive function. For example, the adjusted mean difference (95% confidence interval) for 1 SD increase in WC was -0.48 (-0.97, 0.00). Obese participants in midlife showed an adjusted mean difference (95% confidence interval) of -1.68 (-3.15, -0.22) compared with non-obese. Further adjustment for midlife dietary patterns slightly attenuated these associations. No relationships were observed with verbal memory or global cognitive function. Midlife overall and abdominal adiposity were similarly associated with lower executive functioning scores. Dietary patterns may partly explain such a relationship, arguing for the importance of controlling for lifestyle confounders in future studies.
    The Journal of Nutrition Health and Aging 01/2015; 19(2):183-9. DOI:10.1007/s12603-014-0508-2 · 2.39 Impact Factor